

Applicant Last Name:						
Project Title:						
Date of Submission:						
Section 1: Contact Information						
designa	e contact information for the principal investigator (PI) of the contact information for the proposal on their behalt information as well.	f, please enter the designee's				
1.	Project Title:					
2.	Is this a resubmission of a proposal for a project for which under Catalyze? Yes No	support was previously sought				
3.	Principal Investigator (Last Name, First Name):					
4.	Organization:					
5.	Title:					
6.	Department (or Discipline):					
7.	Street Address:					
8.	City:					
9.	State:					
10.	. Zip code:					
11.	. PI email address:					
12.	. PI telephone number:					
13.	. Name and contact information for corresponding organiza	tional representative, if not the PI:				
14.	. How did you learn about Catalyze? (Select all that apply):					
] [] [NIH/NHLBI website NHLBI Catalyze website NIH Translational Program(s) (e.g., REACH, NCAI, SMARTT, CADET II) Catalyze event My institution/department	 My technology transfer office Scientific conference or news article NIH Program Officer Other (Please specify): 				

1

Confidential

Investigator: _____



Section 2: PI Demographic Profile

Your responses to the following questions allow the Catalyze Coordinating Center to better understand the demographic profile of investigators interested in Catalyze award programs. Your responses to these questions have no influence on proposal selection and will not be shared with reviewers.

15. Position or title:				
16. Terminal Degree:				
17. Year of Terminal Degree (or Expected Completion Year):				
18. Gender: Do you describe yourself as a man, a woman, or in some other way? Man Mon-binary Prefer not to say				
19. Race: What is your race? Please select all that apply				
American Indian or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islander White Other Prefer not to say				
20. Ethnicity: Do you describe yourself as Hispanic or Latino?				
 Hispanic or Latino (A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race) Not Hispanic or Latino Prefer not to say 				
21. Disability Status: Are you disabled?				
☐ Disabled ☐ Not disabled ☐ Prefer not to say				
22. Has your professional experience to-date been characterized by any of the following? Select all that apply:				
 Been granted a copyright, patent, or trademark A patent has been issued Licensed your technology to another party Applied for funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze 				
 Received funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze Founded a start-up company 				

Confidential 2 Investigator: _____



Confidential

Catalyze Regulatory Application Version.6 2024.10.22

ction 3: Technology Profile					
ovide the following information about the project for which Catalyze assistance is sought.					
23.	Disease area (select all that apply):	Lung			
	Cardiovascular/Heart	Sleep			
24.	- Fechnology type (select the product type the):		
25.	Biologic Drug Combination product In vitro diagnostic Health information technology Research tool Gene Therapy Cell Therapy What type of Regulatory support is being redescribe (50-word limit):	Medical devi Are you in o Yes Do you have feasibility? Are there po Yes Is this activito an appromarket? quested from the Catalyze P	ce r near design lock? No data supporting Yes No ptential issues with IP? No ry requiring a modification yed product already on the		
	Do you need assistance with? Please of Preclinical development planning? Developing a regulatory strategy? Reviewing data and performing a gap Assembling documents for FDA meeting Preparing for a meeting with the FDA? Preparing an IND/IDE/510k application Manufacturing development planning Quality Management System? Other?	analysis? ngs (Q-sub, pre-IDE, pre-IND ? n for the FDA?	Yes/No		
	If yes, please describe:				
26. \	What is the specific technology or product (50-word limit)?			
27. '	What is the indication (50-word limit)?				
	If the project is for a therapeutic, what is the Mechanism of Action) for the product (50-w		or, Protein,		

3

Investigator: _____



29. In t	wo or three sentences, what is the technical goal of the project (50-word limit)?		
30. Ind	icate the status of intellectual property protection for this technology No invention disclosure filed with technology transfer office (or equivalent) Invention disclosure filed with TTO (or equivalent) A patent application has been submitted A trademark has been registered A copyright has been granted A patent has been issued		
use	you have efficacy data in a relevant animal model by the route of administration to be ed in the clinic? Please describe relevant efficacy data in the Project Description below. Yes No Not Applicable Other (please specify)		
pro kno	device and diagnostics, have you confirmed conceptualization and proof of concept via stotyping of all or part of the conceived product with supporting data (i.e., animal or own-sample studies) and documentation? Has a Design History File been created? Yes No Not Applicable Other (please specify)		
pro a de the	Dject Description . In 1,000 words or less, please provide an overall description of your bject. Include the project purpose or objective, therapeutic relevance to the NHLBI mission, escription of preliminary studies, a concise description of the studies you are proposing, a unmet market need or innovation to potentially change standard of care, and immercialization path.		
	plain why support for this project is sought from NHLBI and the Catalyze program as cosed to private sector or other sources of support.		
ection 4	ction 4: Prior Technology Development Support		
e following questions request information about the funding and translational program support story for the technology to be developed under the proposed project. Please provide information out NIH and non-NIH support. Please also indicate whether the principal investigator and/or the chnology have been supported by any NIH translational programs.			

Confidential 4 Investigator: _____



35. Were any earlier translational or product development stages supported by any of the following NIH-sponsored translational programs? (select all that apply):
☐ NCAI (B-BIC, UC CAI, or NCAI-CC)
REACH 2015 (UofL ExCITE, MN-REACH, or LIBH)
REACH 2019 (KYNETIC, MBArC, ROI, CO-SPARK, or WE-REACH)
NIGMS STTR Tech Transfer Hubs (ASCEND, DRIVEN, SHARP Hub, Southeast Xlerator Network)
☐ tPPG
POCTRN (CAPCat)
☐ VITA
☐ CADET II
Excellence in Hemoglobinopathies
Molecular Imaging of the Lung
☐ Thrombotic and Hemostatic Centers
Pulmonary Vascular-RV Axis
Preclinical GTRP
Preclinical PACT
Preclinical SMARTT
Transformative Platforms
☐ Bioengineering for HLBS
Large Animal Blood Disease Core
☐ None of the above
Other (Please provide name of NIH opportunity or program):